Single Direct-to-tumor Drug-delivery Device Offers Hope for Treating Triple-negative Breast Cancer
Houston Methodist scientists have developed a nanodevice to deliver immunotherapy without side effects to treat triple-negative breast cancer. Inserted straight into a tumor, this nanofluidic seed makes it possible to deliver a one-time, sustained-release dose that would eliminate the need for patients to undergo several IV treatments over time.
Invented by Alessandro Grattoni, Ph.D., chairman of the Department of Nanomedicine at the Houston Methodist Research Institute, this tiny device is smaller than a grain of rice and, once inserted inside a tumor, can deliver the medication little by little, gradually releasing the drug from its reservoir.
“With this research we are trying to establish a novel strategy to deliver immunotherapy straight into a tumor instead of delivering it to the whole body of a patient,” Grattoni said. “And we’re trying to understand whether delivering it this way would actually be more effective and have less side effects as compared to conventional immunotherapy, which today is given to the entire body of the patient.”
Grattoni and team are not alone in studying ways to administer immunotherapeutics intratumorally. What distinguishes his approach from others is the use of the implantable nanodevice that can be placed inside the tumor very accurately, with just one, simple procedure and with the ability to sustain the delivery of the immunotherapy over a prolonged period of time.
“Timing of the release may be extremely important,” said E. Brian Butler, M.D., chair of the Department of Radiation Oncology at Houston Methodist and Grattoni’s co-senior author on a recent paper in the Journal of Controlled Release. “These immunotherapy payloads Dr. Grattoni created come in a little metal device with nanochannels that release the medication at a constant rate in a controlled way.”
Grattoni, who also is the corresponding author, says that by providing sustained doses, their implant maintains an active level of the drug for extended periods of time. This would reduce the need for continual clinic visits, which are usually required for immunotherapy and other cancer treatments.
By contrast, most other methods currently under preclinical and clinical trials require multiple injections into the tumor and, in many instances, necessitate repeated invasive procedures to access it. Additionally, injecting drugs straight into a tumor as a single dose may not be very effective, as only a part of it will stay, with the rest being rapidly eliminated due to the high-pressure nature of a tumor’s microenvironment. Grattoni’s intratumoral sustained-delivery method prevents this from happening.
“We’re in the middle of an exciting time in medicine, because if we can get it to work, you decrease the toxicities to the patient,” Butler said. “This offers the opportunity of treating locally and getting the systemic response without all the side effects.”
Grattoni likens their device to an hourglass.
“Our implant releases the drug in a constant manner until the entire amount is completely gone from the reservoir,” Grattoni said. “Since it can deliver the immunotherapy by itself for weeks to potentially months, we would only need to place the device inside the tumor once and then the drug would be released autonomously for that long period of time.”
While this platform technology can be applied to many different types of cancer, they chose to work on triple-negative breast cancer, since there’s not currently a good therapeutic approach for treating patients that are affected by the disease.
Breast cancer is traditionally not considered immunogenic, which means it may not respond well to immunotherapy, but triple-negative breast cancer (TNBC) is more immunogenic than other breast cancer subtypes. This is another reason why the researchers chose to focus on it. They are trying to make TNBC more responsive to the treatment with their implant.
“In this study we demonstrated in mice that our intratumoral delivery of immunotherapy was equally effective compared to systemic immunotherapy treatment,” Grattoni said. “The difference was that the systemic immunotherapy showed significant side effects, while our device delivered the same effective treatment without side effects. We were, in fact, able to completely eliminate side effects, which was very surprising to us.”
The next phase of their research, also in mice, will be to combine the device with radiation therapy to see if this approach can improve on the effectiveness currently achieved through systemic delivery of immunotherapy and not just equal it.
“Using Dr. Grattoni’s nanodevice in conjunction with our clinic, we hope to create a very robust immunological response, by putting the immunotherapy directly into the tumor, which is where all the information is,” Butler said. “This will allow us to possibly harness the full power of a person’s immune system to destroy the cancer, offering the opportunity to get the systemic response, while treating locally, without all the side effects.”
In addition to the sustained release system, Grattoni’s nanodevice serves as a fiducial marker to facilitate precise delivery for image-guided radiation. Their hope is that in combination with radiation therapy, this device would not only provide an alternative, but also help improve upon current immunotherapeutic approaches.
“We are hoping to go to patients within three years,” Grattoni said. “We would definitely improve on what is out there currently and what other groups are already studying.”
The Latest on: Immunotherapy
via Google News
The Latest on: Immunotherapy
- Boosting stem cell activity can enhance immunotherapy benefitson November 23, 2020 at 8:03 am
Immune-system T cells have been reprogrammed into regenerative stem cell-like memory (TSCM) cells that are long-lived, highly active "super immune cells" with strong antitumor activity, according to ...
- Immunotherapy Drugs Market Size Analysis, Competitive Landscape, Revenue Status, Future Opportunities and Demand By Top Key Playerson November 23, 2020 at 5:14 am
Global Immunotherapy Drugs Market valued approximately USD 108.5 billion in 2016 is anticipated to grow with a ...
- Immunotherapy Drug Market Size, Historical Growth, Analysis, Opportunities and Forecast To 2021on November 22, 2020 at 10:59 pm
Global immunotherapy drug market is expected to flourish at a CAGR of 13.0% during the forecast period. Moreover, the global immunotherapy drug market is expected to garner noteworthy revenue by the ...
- New Drug Fusing Chemotherapy And Immunotherapy Can Fight Deadliest Cancerson November 21, 2020 at 10:00 pm
Researchers at Harvard’s Wyss Institute have developed a novel treatment methodology, combining chemotherapy and immunotherapy, and they’ve seen it attack Triple-Negative breast cancer.
- Immunotherapy Pioneer Prof. Carl H. June Joins AC Immune’s Board of Directorson November 20, 2020 at 5:42 am
Prof. June is a world authority on immune tolerance and adoptive immunotherapy. Appointment re affirm s AC Immune’s scien tific leadership in neurodegeneration. LAUSANNE, Switze ...
- Insights on the Allergy Immunotherapy Worldwide Industry to 2024 - Increasing Level of Air Pollution is Driving Growthon November 20, 2020 at 3:52 am
The "Global Allergy Immunotherapy (AIT) Market: Size & Forecast with Impact Analysis of COVID-19 (2020-2024 Edition)" report has been added to ResearchAndMarkets.com's offering. This report provides ...
- Seattle biotech firm Umoja Biopharma raises $53M as it tackles unique approach to immunotherapyon November 19, 2020 at 11:59 am
Umoja Biopharma raised $53 million to expand development of its CAR T-cell immunotherapy treatments for blood-based and organ-based tumors in adult and pediatric patients. Founded last ...
- Computational method could predict immunotherapy response in patients with advanced melanomaon November 19, 2020 at 7:21 am
A computational method that combines clinicodemographic variables with deep learning of pre-treatment histology images could predict response to immune checkpoint blockade among patients with advanced ...
- Another side to cancer immunotherapy? Scientists investigate intratumoral B cellson November 19, 2020 at 4:11 am
Immunotherapies have transformed the treatment of several types of cancer over the last decade. Yet they focus on reactivating one arm of the immune system: cytotoxic T cells, which sniff out and kill ...
via Bing News